Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
IMPEL PHARMACEUTICALS INC amended credit facility of approximately $121.5 million with Oaktree Fund Administration, LLC at SOFR + 10.75% maturing December 31, 2023.
- Instrument
- credit facility
- Principal
- approximately $121.5 million
- Counterparty
- Oaktree Fund Administration, LLC
- Rate
- SOFR + 10.75%
- Maturity
- December 31, 2023
- Event
- amendment
Exact text from the filing
the “Original Agreements”). The Amended Credit Agreement provides for an aggregate principal loan amount to the Company by the existing and new lenders of approximately $121.5 million, including up to $20 million in additional cash proceeds to the Company from the making of additional term loans, the exchange of approximately $96.5 million of outstanding
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
IMPEL PHARMACEUTICALS INC amended Second Amendment to Credit Agreement and Guaranty and Revenue Interest Financing Agreement with Oaktree Fund Administration, LLC valued at $121,500,000 aggregate principal loan amount (effective 2023-09-05).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Oaktree Fund Administration, LLC
- Value
- $121,500,000 aggregate principal loan amount
- Effective
- 2023-09-05
Exact text from the filing
On September 5, 2023, Impel Pharmaceuticals Inc. (the “Company”) entered into the Second Amendment to Credit Agreement and Guaranty and Revenue Interest Financing Agreement (the “Amended Credit Agreement ”) with Oaktree Fund Administration, LLC as administrative agent, and the existing and new lenders party thereto (collectively, the “Secured Parties”), which amends the Company’s (i) Credit Agreement and Guaranty dated March 17, 2022, as amended on August 21, 2023, and (ii) the Revenue Interest Financing Agreement dated March 17, 2022, as amended on August 21, 2023 (the “ RIF Agreement”) (collectively, the “Original Agreements”).
View on SEC.gov